A Phase I, Open-Label Dose Escalation and Dose Expansion Study of Intravenous GFH009 Single Agent in Patients with Relapsed/Refractory Hematologic Malignancies
Sponsor: |
GenFleet Therapeutics |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAT5785 |
U.S. Govt. ID: |
NCT04588922 |
Contact: |
Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
The purpose of this study is to assess the safety, effectiveness, pharmacokinetic (PK how long the drug is in your body and how it is metabolized) and pharmacodynamics (PD where does the drug go in your body and what is its biological effect) of the study drug, GFH009, in patients with relapsed or refractory hematologic malignancies including acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or other lymphomas. This is the first time GFH009 is being studied in humans.
This study is closed
Investigator
Andrew Lipsky, MD
Are you age 18 or older? |
Yes |
No |
Have you been diagnosed with a hematologic malignancy (blood cancer)? |
Yes |
No |
Do you have a history of HIV infection? |
Yes |
No |
Do you have a history of chronic or current Hepatitis B or Hepatitis C infection? |
Yes |
No |